

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home	Quick	Advanced	Pat Num	Help
	Hit List	Next	Bottom	
	View Cart	Add to Cart		
	Images			

(1 of 26)

United States Patent

6,410,570

Fernandez-Pol

June 25, 2002

Methods of inactivating a virus and controlling viral replicationAbstract

An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes required for growth, replication or inflammatory response. The preparations can be administered systemically or for topical use. The preparations have antineoplastic, antiviral, antiinflammatory and antiproliferative effects and are used in the treatment of warts, psoriasis, acne, skin cancers, sunburn and other proliferative diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS. The agents also can be used to induce autologous immunological response.

Inventors: Fernandez-Pol; Jose A. (Chesterfield, MO)

Assignee: Novactyl, Inc. (St. Louis, MO)

Appl. No.: 657989

Filed: September 8, 2000

Current U.S. Class: 514/354; 435/238; 435/236; 514/13; 514/356; 514/934

Intern'l Class: A61K 031/44; C12N 007/06

Field of Search: 514/13,354,356,934 435/238,236

References Cited [Referenced By]

U.S. Patent Documents

<u>3903285</u>	Sep., 1975	Umesawa et al.
<u>4044140</u>	Aug., 1977	Sherlock.

Aulakh, Charanjit S.
Primary Examiner
United States Patent and Trademark Office
Commissioner of Patents and Trademarks
Washington, DC 20231

Reference:

1. Fernandez-Pol, USA patent 6,410,570, June 25, Methods of inactivating a virus and controlling viral replication Examiner: Examiner: Aulakh, Charanjit S.

Subject: AUTHORSHIP RESPONSIBILITY

Dear Examiner: Aulakh, Charanjit S.:

By signing this document, I certify that I have not participated sufficiently in the conception and design of this work, the analysis of the data (where applicable) as well as in the writing of the patent referenced above, to take public responsibility for it. I cannot warrant that the patents represent valid original work, since I have not even seen a substantial portion of the data presented. I have reviewed the original version of the patent and did not approve its submission without the necessary corrections. Neither this patent nor others with similar content under my authorship should be published without the correction of errors that I indicated in writing to both Novactyl's patent attorneys and to the Board of Directors. Furthermore, I attest that a portion of the data on which the patent is based have never been shown to me by the management. Thus, the management has to produce the data on which this patent is based. The undersign cannot warrant that the patents contain no libelous or unlawful statements, that they do not infringe on the rights of others, or contain material or instructions that might cause harm or injury, particularly in reference to patient treatments which represent cases introduced by the management.

Sincerely,



Jose A. Fernandez-Pol, M.D.
437 Hunters Hill Dr.
Chesterfield, MO 63917-3446

TE: 314-275-7856

P.S.: The management at the time of patent application and prosecution of the patents indicated above were: Michael Douglas, Ph.D., Vice President & Chief Scientific Officer, Mr. Raymond Zipprich, Vice President, Chief Operating Officer & Chief Financial Officer, and Avinash Amin, M.D., Vice President, Clinical Affairs.

Novactyl, Inc
1816 Lackland Hill Parkway, Suite 220
St. Louis, Missouri 63146
Telephone: 314-991-3890
e-mail: zipprich@Novactyl.com